W K Tonui1. 1. Centre for Biotechnology Research and Development, Kenya Medical Research Institute, PO Box 54840, Nairobi, Kenya.
Abstract
OBJECTIVE: To determine whether Leishmania donovani-derived lipophosphoglycan (LPG) can confer cross-protection to L. major in susceptible BALB/c mice model. METHODS: BALB/c mice were immunised with a total dose of 30 microg of LPG plus 150 microl of mycobacterium bovis Bacille Calmette guerin (BCG) and later challenged with virulent L. Major parasites. RESULTS: This study demonstrated an activation of both the humoral as well as cell-mediated response to LPG mixed with BCG which correlated with resistance against the disease. However, immunised mice were not protected compared to their PBS controls. CONCLUSION: Though L. donovani infections have been shown to confer cross-protection to L. major this may not be true for purified antigens.
OBJECTIVE: To determine whether Leishmania donovani-derived lipophosphoglycan (LPG) can confer cross-protection to L. major in susceptible BALB/c mice model. METHODS: BALB/c mice were immunised with a total dose of 30 microg of LPG plus 150 microl of mycobacterium bovis Bacille Calmette guerin (BCG) and later challenged with virulent L. Major parasites. RESULTS: This study demonstrated an activation of both the humoral as well as cell-mediated response to LPG mixed with BCG which correlated with resistance against the disease. However, immunised mice were not protected compared to their PBS controls. CONCLUSION: Though L. donovaniinfections have been shown to confer cross-protection to L. major this may not be true for purified antigens.
Authors: Eva Iniguez; Nathaniel S Schocker; Krishanthi Subramaniam; Susana Portillo; Alba L Montoya; Waleed S Al-Salem; Caresse L Torres; Felipe Rodriguez; Otacilio C Moreira; Alvaro Acosta-Serrano; Katja Michael; Igor C Almeida; Rosa A Maldonado Journal: PLoS Negl Trop Dis Date: 2017-10-25